Kunming, China, February 15, 2022
The FDA (USA) has recently approved of the clinical trial on the investigational new drug B1344 for the treatment of nonalcoholic steatohepatitis (NASH). https://med.sina.com/article_detail_100_2_111927.html
KBI, Shanghai Institute of Nutrition and Health and Tasly have jointly evaluated the efficacy and safety of B1344 in KBI's monkey model of NASH. The results showed that B1344 is safe and ameliorates all NASH pathology characteristics, particularly hepatic fibrosis. These findings were reported in Diabetes (doi.org/10.2337/db20-0209) where KBI’s NASH model and methods (including pharmacodynamics and pharmacokinetics) were detailed.
This research received an editorial commentary by the invited experts in the field (doi.org/10.2337/dbi20-0025). It is another report in high-impact journals about KBI’s studies on metabolic diseases in monkey models:
https://www.kbimed.com/NewsDis-b5915e15c2844378b787eed64a5bf5ca.htm
Contact us if you need more information.